Abstract
AimsGlycoprotein VI (GPVI) is a key platelet receptor which mediates plaque-induced platelet activation and consecutive atherothrombosis, but GPVI is also involved in platelet-mediated atheroprogression. Therefore, interference in GPVI-mediated platelet activation has the potential to combine short-term and long-term beneficial effects, specificity and safety especially regarding bleeding complications.Methods and ResultsWe investigated the effects of the soluble dimeric GPVI receptor fusion protein, Revacept, an antagonist of collagen-mediated platelet activation, in an animal model of atherosclerosis: twenty week old rabbits, which had been fed on a cholesterol-rich diet for 8 weeks, received Revacept (8 mg/kg) or control twice weekly for 4 weeks. Pharmacokinetics indicated a slight accumulation of the drug in the serum after repeated dosing of Revacept for 3 weeks. A significant improvement of endothelial dysfunction after 0.06 and 0.6 µg/min acetylcholine and a significant decrease of vessel wall thickening were found after Revacept treatment. Accordingly, aortic vessel weight was reduced, and plaque sizes, macrophage and T-cell invasion tended to be reduced in histological evaluations. Bleeding time was determined after tail clipping in mice. Revacept alone or in combination with widely used anti-platelet drugs revealed a high safety margin with no prolongation of bleeding times.ConclusionRepeated doses of Revacept led to a significant improvement of endothelial dysfunction and vascular morphology in atherosclerotic rabbits. Furthermore, no influence of Revacept on bleeding time alone or in combinations with various anti-platelet drugs was found in mice. Thus, the inhibition of collagen-mediated platelet interaction with the atherosclerotic endothelium by Revacept exerts beneficial effects on morphology and vascular function in vivo and seems to have a wide therapeutic window without influencing the bleeding time.
Highlights
Rupture of atherosclerotic plaques leads to adhesion of circulating platelets to exposed sub-endothelial matrix proteins which trigger subsequent platelet activation and aggregation
Repeated doses of Revacept led to a significant improvement of endothelial dysfunction and vascular morphology in atherosclerotic rabbits
No influence of Revacept on bleeding time alone or in combinations with various anti-platelet drugs was found in mice
Summary
Rupture of atherosclerotic plaques leads to adhesion of circulating platelets to exposed sub-endothelial matrix proteins which trigger subsequent platelet activation and aggregation. Revacept is a dimeric recombinant fusion protein consisting of the Fc part of a human immunoglobulin G (IgG) together with the hinge region and the functional GPVI domain at the N-terminus (GPVI-Fc) [1] This novel antiplatelet tool has been proven beneficial in various animal models of acute vascular injury [1,9]. Human GPVI-Fc/Revacept is thought to act by blocking the binding sites of platelets at collagen, fibronectin [8,11] and possibly other vascular ligands, such as von Willebrand factor, and might interfere with platelets in acute plaque rupture and during chronic interaction with the activated but intact atherosclerotic endothelium
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.